Abstracts tagged "B-Lymphocyte"

Abstract Number: 0004 • ACR Convergence 2023
CD22 X CD79b Bispecific Ab Potently Inhibits B Cell Activation and Plasmablast Accumulation
Timothy Burwell¹, Jeffrey Hall¹, Suzanne Cole², Sarah Tursi¹, Isabelle Baribaud³, Kyle Bednar¹, Naresh Kumar¹, Julie Carman¹, Navin Rao² and Edith Janssen², ¹Janssen Research and Development, LLC, Spring House, PA, ²Janssen Research & Development, LLC, Spring House, PA, ³IGM Biosciences, Inc., Doylestown, PA
Background/Purpose: B cells contribute to the development and progression of autoimmune diseases through multiple mechanisms. Consequently, modulating B cell activation, B cell effector function, and…
Abstract Number: 0925 • ACR Convergence 2023
IL-4 Acts Through Aryl Hydrocarbon Receptor to Antagonize TLR7-induced Double Negative 2 B Cells in Lupus
Changming Lu, Hui-chen Hsu, Min Gao, Jose Rubio, Winn Chatham and John Mountz, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: We recently showed that in SLE, IL-4 suppressed the development of interferon-beta (IFNβ) and TLR7-stimulated T-bet+ double negative 2 (DN2) B cells. Here we…
Abstract Number: 2583 • ACR Convergence 2023
A Predictive Model for Progression to Clinical Arthritis Based on Lymphocyte Subsets and ACPA in At-risk Individuals with Arthralgia
Klára Prajzlerová¹, Olga Kryštůfková², Nikola Kaspříková³, Nora Růžičková², Hana Hulejová¹, Petra Hánová¹, Jiri Vencovsky⁴, Ladislav Senolt⁵ and Maria Filkova², ¹Institute of Rheumatology, Prague, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ³Faculty of Informatics and Statistics, Prague University of Economics and Business, Prague, Czech Republic, ⁴Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁵Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Praha, Czech Republic
Background/Purpose: The positivity of antibodies against citrullinated proteins (ACPA) substantially increases the risk of developing rheumatoid arthritis (RA). The definition of individuals with arthralgia at…
Abstract Number: 0007 • ACR Convergence 2023
Targeting NF-κB Signalling in B Cells from ANCA-associated Vasculitis Impairs B Cell Biology as a Potential Novel Target
Ana Merino-Vico¹, Jan Piet van Hamburg¹, Paul Tuijnenburg¹, Aram Al-Soudi¹, Carlo Bonasia², Boy Helder¹, Abraham Rutgers², Wayel H. Abdulahad², Coen A. Stegeman², Jan-Stephan Sanders², Laura Bergamaschi³, Paul A. Lyons³, Theo Bijma², Laura Van Keep¹, Kirsten wesenhagen¹, Aldo Jongejan¹, Henric Olsson⁴, Niek De Vries¹, Taco W. Kuijpers¹, Peter Heeringa² and Sander Tas⁵, ¹Amsterdam University Medical Centers, Amsterdam, Netherlands, ²University Medical Center Groningen, Groningen, Netherlands, ³University of Cambridge, Cambridge, United Kingdom, ⁴AstraZeneca, Gothenburg, Sweden, ⁵Amsterdam UMC, locatie AMC, Utrecht, Netherlands
Background/Purpose: B cells have gained increased interest in ANCA-associated vasculitis (AAV) research, as the treatment of this autoimmune disease with rituximab (an anti-CD20 B cell…
Abstract Number: 0928 • ACR Convergence 2023
Skewing of B Cell Receptor Repertoire in Unswitched Memory B Cells Is Associated with Disease Activity of Systemic Lupus Erythematosus and Targeted by Belimumab
Keishi Fujio¹, Mineto Ota¹, Masahiro Nakano², Yasuo Nagafuchi³, Satomi Kobayashi¹, Hiroaki Hatano², Ryochi Yoshida¹, Yuko Akutsu¹, Takahiro Itamiya¹, Nobuhiro Ban⁴, Yumi Tsuchida¹, Hirofumi Shoda¹, Kazuhiko Yamamoto⁵, Kazuyoshi Ishigaki⁶ and Tomohisa Okamura⁷, ¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ²Laboratory for Autoimmune Diseases, RIKEN Center for Integrative Medical Sciences, Tokyo, Japan, ³Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ⁴Research Division, Chugai Pharmaceutical Co., Ltd., Yokohama, Japan, ⁵Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo and Laboratory for Autoimmune Diseases, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan, ⁶RIKEN, Tokyo, Japan, ⁷Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo and Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
Background/Purpose: Despite the involvement of B cells in the pathogenesis of immune-mediated diseases, the biological mechanisms underlying their function are poorly understood. To address this…
Abstract Number: 2602 • ACR Convergence 2023
Spatially Resolved Cellular Signatures Predict Corticosteroid Treatment Response in Giant Cell Arteritis
Cecilia Ansalone¹, Sam McAllister², Ethan Pickerill³, Lin Zhang³, Annie Peacock², Dominic McGovern⁴, Holly Leslie⁵, Victoria Kellior², Evelyn Qian², David Gemperline³, Aysin Tulunay Virlan², Sylvia Wright⁶, Paul Cauchi⁶, Timothy Beckman⁶, Lisa Hutton⁶, John Cole¹, Isabella Wulur³, Robert Benschop³, Nigel Jamieson⁵, Carl Goodyear¹ and Neil Basu¹, ¹University of Glasgow, Glasgow, United Kingdom, ²University of Glasgow - School of Infection & Immunity, Glasgow, United Kingdom, ³Eli Lilly and Company, Indianapolis, IN, ⁴University of Glasgow - School of Medicine, Glasgow, United Kingdom, ⁵University of Glasgow - School of Cancer Sciences, Glasgow, United Kingdom, ⁶NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
Background/Purpose: Corticosteroids (CS) remain the mainstay of giant cell arteritis (GCA) therapy. Between ~30-70% patients relapse following CS taper and are consequently at risk of…
Abstract Number: 0014 • ACR Convergence 2023
The 330 Genetic Risk Loci of Systemic Lupus Erythematosus (SLE) Now Known Are Consonant with Multiple Causal Mechanisms Involving Epstein-Barr Virus (EBV)-Encoded Transcription Co-factors (TFs) in EBV-Infected B Cells
Viktoryia Laurynenka¹, Xiaoting Chen², sreeja Parameswaran², Leah Kottyan², Matthew Weirauch², Iouri Chepelev³, Kenneth Kaufman³ and John Harley³, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³US Department of Veterans Affairs Medical Center, Cincinnati, OH
Background/Purpose: Association of EBV infection with SLE, data suggesting an anti-EBNA1 molecular mimicry fostering SLE autoimmunity, and mechanisms in EBV infected B cells support a…
Abstract Number: 0932 • ACR Convergence 2023
The Landscape of Immune Cells in Systematic Lupus Erythematosus Patients with Epstein-Barr Virus Infection by Single-cell Sequencing
Lingzhen Hu¹, Jianxin Tu¹, Jiajun Gui², Mengyuan Fang², Xiaowei Chen¹ and Li Sun¹, ¹The First Affliated Hospital of Wenzhou Medical University, Wenzhou, China, ²The First Clinical College, Wenzhou Medical University, Wenzhou, China
Background/Purpose: This study aimed to analyze the immune cell profiles, especially B cells and B-cell receptor (BCR) of systematic lupus erythematosus (SLE) patients with or…
Abstract Number: 0082 • ACR Convergence 2023
A VAV1-Directed Molecular Glue Degrader, MRT-6160, Reduces Joint Inflammation in a Collagen-Induced Arthritis Autoimmune Disease Model
Adam Cartwright¹, Foram Desai², Sophia Nguyen², Alexandra Trouilloud², Elisa Liardo¹, Daric Wible², Ilaria Lamberto², Bradley Demarco², Chris King², Debora Bonenfant¹, Sharon Townson², Owen Wallace², Filip Janku², Laura McAllister¹, Alison Paterson² and Marisa Peluso², ¹Monte Rosa Therapeutics, Basel, Switzerland, ²Monte Rosa Therapeutics, Boston, MA
Background/Purpose: VAV1 is a member of the VAV family of guanine nucleotide exchange factors (GEFs) and plays a critical role in mediating T- and B-cell…
Abstract Number: 0951 • ACR Convergence 2023
Single Cell Analysis of Transitional B Cells in Systemic Sclerosis Highlights Defective Peripheral Tolerance
Claire Beesley¹, Nina Goldman¹, David Abraham¹, Christopher Denton¹, Rizgar Mageed² and Voon Ong³, ¹University College London, London, United Kingdom, ²Queen Mary University of London, London, United Kingdom, ³UCL Medical School Royal Free Campus, London, United Kingdom
Background/Purpose: Transitional B cells comprise a distinct population of B cells that have recently migrated to the periphery from the bone marrow. In systemic sclerosis…
Abstract Number: 0105 • ACR Convergence 2023
Characterization of B-Cell Subsets in Antiphospholipid Syndrome Patients: Implications for Disease Phenotype and Pathogenesis
Yin Long¹, Jiuliang zhao², Mengtao Li² and Xiaofeng Zeng², ¹Peking Union Medical College Hospital Department of Rheumatology and Clinical Immunology, Beijing, China, ²Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Background/Purpose: Primary antiphospholipid syndrome (PAPS) is an autoimmune disorder characterized by the presence of pathogenic autoantibodies. The key immune cell subsets change in PAPS patients…
Abstract Number: 1227 • ACR Convergence 2023
Serious Infections Following Rituximab Administration in Children with Systemic Lupus Erythematosus
Jordan Roberts¹, Anna Faino², Mersine Bryan¹, Jonathan Cogen¹ and Esi Morgan¹, ¹Seattle Children's Hospital, Seattle, WA, ²Seattle Children’s Research Institute, Seattle, WA
Background/Purpose: Rituximab has been associated with high rates of infection among adults with systemic lupus erythematosus. However, studies of infection risk following rituximab among children…
Abstract Number: 0212 • ACR Convergence 2023
The Impact of Immunosuppression on the Humoral Immunogenicity of SARS-CoV-2 mRNA Vaccines in SLE
Rebecca Sadun¹, Dan Crair², Emmanuel B Walter³, Jennifer Rogers¹, Megan Clowse⁴, Amanda Eudy⁵, Kai Sun¹, Jayanth Doss¹, Lisa Criscione-Schreiber⁶, Sarah Valencia² and M. Anthony Moody⁶, ¹Duke University, Durham, NC, ²Duke Human Vaccine Institute, Durham, NC, ³Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, ⁴Duke University, Chapel Hill, NC, ⁵Duke University, Raleigh, NC, ⁶Duke University School of Medicine, Durham, NC
Background/Purpose: The ACR's COVID-19 Vaccine Guidance recommends all patients with rheumatic diagnoses be vaccinated against SARS-CoV-2. The predominant SARS-CoV-2 vaccines used in the United States…
Abstract Number: 1370 • ACR Convergence 2023
Synthetic Glabridin Derivatives Improves Sjogren’s Syndrome by Inducing Salivary Secretion and Salivary Gland Regeneration
Eui-Jong Kwon¹, Jin-Sil Park², Ha Yeon Jeong³, Hye Yeon Kang⁴, JeongWon Choi³, Mi-La Cho³ and Sung-Hwan Park⁵, ¹Division of Rheumatology, Department of Internal Medicine, The Catholic University of Korea Seoul St. Mary's Hospital, Seocho-gu, South Korea, ²The Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seocho-gu, South Korea, ³Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁴Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seocho-gu, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Sjogren’s syndrome (SS) is a systemic autoimmune disease characterized by infiltration of lymphocytes into the exocrine gland resulting in progressive lacrimal and salivary estruction…
Abstract Number: 0274 • ACR Convergence 2023
A Mix-and-match COVID-19 Vaccination Strategy in Patients with Rheumatic Diseases on Rituximab
Nathalie Amiable¹, Mehdi Benlarbi², Mathieu Dube³, Sonia Theriault⁴, Alexandra Godbout¹, Anne-Sophie Julien⁵, Gloria-Gabrielle Ortega-Delgado⁶, Melina Duchesne⁷, Rose Cloutier⁸, Josee Perreault⁹, Annie Gravel¹⁰, Lison Fournier¹¹, Giuliana Alfonso¹², Josiane Bourre-Tessier¹³, Marie Hudson¹⁴, Nicolas Richard¹⁵, Jean-Paul Makhzoum¹⁶, Arielle Mendel¹⁷, Sasha Bernatsky¹², Marc Dionne¹⁸, Michael Libman¹⁹, Gaston De Serres²⁰, Mélanie Dieudé²¹, louis Flamand²², Daniel Kaufmann²³, Andrés Finzi²⁴, Renée Bazin²⁵, Ines Colmegna²⁶ and Paul R. Fortin²⁷, ¹Centre ARThrite - CHU de Quebec - Universite Laval, Quebec City, QC, Canada, ²CRCHUM, Université de Montréal, Montreal, QC, Canada, ³Centre de recherche du Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada, ⁴The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁵Département de mathématiques et statistique, Université Laval, Québec, QC, Canada, ⁶Centre de Recherche du CHUM, Montreal, QC, Canada, ⁷Centre de recherche du Centre Hospitalier de l'Universitaire de Montréal, Montreal, QC, Canada, ⁸Centre de recherche hospitalier de l'Université de Montréal, Montreal, QC, Canada, ⁹Hema-Quebec, Quebec City, QC, Canada, ¹⁰CHU de Québec - CHUL Axe des Maladies Infectieuses et Immunitaires, Quebec City, QC, Canada, ¹¹Centre de recherche du CHU de Quebec - Université Laval, Quebec City, QC, Canada, ¹²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹³Centre hospitalier de l'Université de Montréal (CHUM), Université de Montréal, Montréal, QC, Canada, ¹⁴McGill University, Montréal, QC, Canada, ¹⁵Hopital Maisonneuve Rosemont, Montreal, QC, Canada, ¹⁶Vasculitis Clinic, Canadian Network for Research on Vasculitides, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ¹⁷McGill University Health Centre, Montréal, QC, Canada, ¹⁸Centre de recherche du CHU de Québec - Université Laval, Quebec City, QC, Canada, ¹⁹McGill Centre for Viral Diseases, Montreal, QC, Canada, ²⁰Centre de recherche du CHU de Québec – Université Laval, Quebec City, QC, Canada, ²¹Microbiology, Infectiology and Immunology Department, Faculty of Medicine, Université de Montréal, CHUM Research Center, Héma-Québec, Montreal, QC, Canada, ²²Centre ARThrite - CHU de Quebec - Université Laval, Quebec City, QC, Canada, ²³University of Montreal, University of Lausanne, Lausanne University Hospital, Montreal, QC, Canada, ²⁴Université de Montréal, Montreal, QC, Canada, ²⁵Héma-Québec, Affaires Médicales et Innovation, Quebec City, QC, Canada, ²⁶The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ²⁷Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada
Background/Purpose: Patients with rheumatic diseases (RD) on rituximab (RTX) have increased mortality following COVID-19 and reduced antibody response post-vaccine. We tested whether a mix-and-match strategy…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.